Related Experiment Video

Updated: Aug 24, 2026

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
10:05

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Published on: November 13, 2015

Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity

Anne Aries1, Pierre Paradis, Chantal Lefebvre

  • 1Laboratory of Cardiac Growth and Differentiation, Institut de Recherches Cliniques de Montréal, Montréal, QC, Canada H2W 1R7.

Proceedings of the National Academy of Sciences of the United States of America
|April 22, 2004
PubMed

Insights

Transcription factor GATA-4 protects adult heart cells from apoptosis and drug-induced damage. Enhancing GATA-4 levels can prevent heart failure by regulating cardiomyocyte survival.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cellular Stress Response

Background:

  • Myocyte apoptosis is a primary driver of heart failure, yet its regulation remains poorly understood.
  • Understanding cardiomyocyte survival mechanisms is critical for developing effective heart failure therapies.

Purpose of the Study:

  • To investigate the role of transcription factor GATA-4 in regulating cardiomyocyte survival.
  • To determine if GATA-4 acts as a protective factor against drug-induced cardiotoxicity.

Main Methods:

  • Investigated GATA-4's function in differentiated, postnatal cardiomyocytes.
  • Examined the effect of doxorubicin on GATA-4 levels and cardiomyocyte apoptosis.
  • Utilized mouse models with Gata4 gene alterations to assess susceptibility to cardiotoxicity.
  • Assessed the impact of genetic or pharmacologic GATA-4 enhancement on apoptosis and cardiotoxicity.

Main Results:

  • Transcription factor GATA-4 functions as a survival factor for cardiomyocytes.
  • GATA-4 is an upstream activator of the antiapoptotic gene Bcl-X.
  • Doxorubicin-induced cardiotoxicity involves the depletion of GATA-4, leading to cardiomyocyte apoptosis.
  • Mice with a null Gata4 allele exhibit increased susceptibility to doxorubicin cardiotoxicity.
  • Enhancing GATA-4 levels protects against cardiomyocyte apoptosis and doxorubicin-induced cardiotoxicity.

Conclusions:

  • GATA-4 is an essential antiapoptotic factor crucial for the adult heart's adaptive stress response.
  • Tissue-specific transcription factors can modulate apoptosis-related genes, offering a therapeutic strategy for cell-specific apoptosis regulation in diseases.
  • Targeting GATA-4 represents a potential therapeutic avenue for preventing heart failure and drug-induced cardiotoxicity.

More Related Videos

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis06:59

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis

Published on: August 11, 2010

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...